Spearheading Safety, Clinical Efficacy and Regulatory Compliance Using Advanced Genetic Engineering and Novel Delivery Platforms to Shape the Next Era of Genome Editing
The FDA has shown its' hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly. Regulators want genome editing therapies to reach patients. Biopharma are also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options.
But intent and support alone won't get these therapies to patients. Developmental, manufacturing and regulatory challenges still stand between the lab and the patients waiting.
That's why the 7th Genome Editing Therapeutics Summit returns to Boston in 2026 where R&D, preclinical, translational, regulatory and c-suite leaders will come together to answer one question: how do we maximize the application of genome editing therapies to patients who need them most?
Don't miss out on insights from AbbVie, Bristol Myers Squibb, Intellia Therapeutics, Beam Therapeutics, Sanofi and others on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.
A good collection of scientific talks from both gene editing tools and delivery methods.
2025 Attendee, Senior Scientist, BioNTech
This summit represents an important forum to align on how we collectively move genome editing therapies forward, from scientific innovation to safe, scalable clinical applications. I’m looking forward to sharing a risk-based view of off-target biology and learning how others are addressing the same regulatory and translational challenges across the field.
2026 Speaker, Senior Director, Genomics & Computational Biology, Beam Therapeutics
Good mix of talks that covered the genome editing field, with mostly cutting-edge material.
2024 Attendee, Professor, Translational Research, University of Pennsylvania
Attending Companies Include
Explore the Full Event Guide
- 3 days of content to find the sessions your program needs most
- 50:50 clinical and preclinical speakers to find genome editing talks relevant to your development stage
- 80% Directors, VPs and C-suite to benchmark your genome editing strategy against the right decision-makers
- 64% in vivo & 36% ex vivo agenda to fit your route of delivery
- See how Intellia, Beam Therapeutics and others closest to approval are contributing to the meeting
Official Partners
Explore Related Events
Explore the Agenda
See exactly which delivery, manufacturing and regulatory sessions are relevant to your genome editing program.
Partner With Us
Put your solutions in front of the genome editing decision-makers actively looking for them.
Join Genome Editing Experts
Connect with the R&D, clinical and regulatory leaders driving genome editing therapeutics forward.